{
  "doc_id": "2018-10-01_Informationen-zVT_Lenvatinib-D-379",
  "created_date": "2017",
  "country": "AT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Criteria Vergleic",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "und",
      "text": "Recherc der zwec SGB V Process Status: Decem n zur Bestherapi",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "sche and Sy",
      "text": "Inferior g: 2017-B mber 2017 timmung der zwe ie Synopse der Evid en Vergleichsther -221 Lenvatinib eck den rap kmässig nz zum B pie nach gener Bestimmung h § 35a",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "I. Appropriate comparative therapy: criteria according to 5. Chapter § 6 VerfO G-BA",
      "text": "Lenvatinib [used to treat hepatic cell carcinoma]",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Criteria according to Chapter 5, § 6 VerfO",
      "text": "If a medicinal product application is considered as a comparative therapy, the medicinal product must in principle have a See Overview \"II. Approved medicinal products in the area of application- approval for the area of application- approval. If a non-medicinal treatment is not considered as an appropriate comparative therapy, it must be considered as part of the treatment. It is assumed that both curative treatment (corresponding to GKV) can be achieved. BCLC stage 0 and A) as well as locoregional therapy at BCLC stage B, in particular transarterial (chemo) embolisation (TACE or TAE), is not (more) eligible. Decisions/assessments/recommendations of the Joint • Measures for quality assurance in proton therapy in patients and patients with Federal Committee to be approved in the area of application-approved inoperable hepatocellular carcinoma; Decision of 16 July 2009 and 27 November 2015 Medicines/non-medicamentous treatments • Assessment according to § 137h SGB V: Ultrasound-controlled high-intensive treatment of the stand-extensive drug",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "Trade name",
      "text": "The medicinal product to be evaluated is: Lenvatinib Preliminary indication: L01XE29 Lenvatinib is indicated for the treatment of liver cell carcinoma Lenvima® mitomycin Mitomycin is used in palliative tumour therapy. L01DC03 In intravenous administration, it is effective in monochemotherapy or in combined cytostatic (generic) metastatic tumours: [...] − advanced liver cell carcinoma Sorafenib liver cell carcinoma L01XE05 Nexavar is indicated for the treatment of liver cell carcinoma (see section 5.1). Nexavar® Regorafenib1 Stivarga is indicated as monotherapy for the treatment of adult patients m L01 XE21 - hepatocellular carcinoma (HCC), previously treated with sorafenib.",
      "start_page": 3,
      "end_page": 5
    },
    {
      "heading": "Systematic research:",
      "text": "A systematic literature search for systematic reviews, meta-analysis, HTA reports and evidence-based systematic guidelines for the indication of liver cell carcinoma was conducted. The search period was limited to the last 5 years and the search was completed on 02.10.2017. The search was carried out in the following databases or web pages of the following organisations: The Cochrane Database of Systematic Reviews, Health Technology Assessment Database, MEDLINE (PubMed), AWMF, Clinical Evidence, CCO, DAHTA, ESMO, G-BA, GIN, IQWiG, NCCN, NCCN, NCI, NICE, TRIP, SIGN, WHO. A free internet search was completed according to current German and European guidelines. The detailed presentation of the search strategy is listed at the end of the synopsis. The search resulted in 1421 sources, which were subsequently examined in a two-stage screening procedure for topic relevance and methodological quality. In addition, a language retrieval was performed on German and English sources.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Indication:",
      "text": "For the treatment of liver cell carcinoma Abkurzu Akdae AWMF ÄZQ CASP CCO DAHTA DCR DRKS ESMO GBA GIN HCC HFSR ICTRP IQWiG ISRCT MPV NCCN NCI NGC NHS C NICE OS PEI/PA PVB SIGN TACE TAE TRIP TTP TTSP WHO ungen e F A O P G TN N CRD AI n: Arzneimittelkommission der deutschen Ärzteschaf Arbeitsgemeinschaft der wissenschaftliche mediz Fachgesellschaften Medical Center for Quality in Medicine Critical Appraisal Skills Programs Cancer Care Ontario German Agency for Health Technology Assessment disease control rate German Register Clinical Studies European Society for Medical Oncology Joint Federal Committee Guidelines International Network hepatocellular carcinoma hand and foot skin reactions International Clinical Trials Registry Platform Institute for Quality and Economicality in Gesun International Standard Random Control Center Dreating Network Services National Care National Overview",
      "start_page": 5,
      "end_page": 8
    },
    {
      "heading": "Cochrane Reviews",
      "text": "1st question to assess the comparative benefit and harm of differential interventions in the treatment of intermediate-stage hepatocellular carcinoma • through a network meta-analysis and to generate rankings of the ava interventions according to their safety and efficiency. Population: Participants with intermediate-stage hepatocellular carcinoma (BCLC stage B) irrelevant of the presence of cirrhosis, size and number of the tumours (provised they met the criterion of intermediate-stage hepatocellular carcinoma), presence or absence of portal hypertensio aetiology of hepatocellular carcinoma, and the future remnant liver volume. Randomis isolated accidents in pregnancy.",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "3. Presentation of results",
      "text": "Quality of studies: The overall quality of evidence was low or very low and all the trials were at high risk of bias. • Over 18 to 30 months, 50% to 75% of participants diet. There was no evidence of any difference between the people who received chemotherapy and those who did not receive chemotherapy. • None of the trials reported complaints, health-related quality of life (a measure of a person) satisfaction with their life and health), cancer response, or length of hospital stay. • Overall, there is currently no evidence for benefit of any active treatment in addition to supportive treatment for intermediate-stage hematocellular cardioma.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Systematic reviews",
      "text": "1. Question This systematic review suggests to examine the role of TACE in the treatment of HCC with PVT in either the main portal vein (MPV) or portal vein branches o (PVB). ar y y s carcinom portal ve thrombo systema and me van Ro BV et a System of trans emboliz hepatoc ma with a tumor osis: an atic review eta-analysis osmalen",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "al., 2017",
      "text": "atic review sarterial zation for cellular population: HCC patients with PVT. Intervention / comparator: comparing TACE to another treatment for w management of HCC with PVT s Endpoints: overall survival (OS), mRECIST response, and comparison incidence Search period (actuality of research): PubMed was searched from January 1, 2006 to August 31, 2016. Number of included studies/patients (total): 13 studies with 1933 TACE patients were included. Quality assessment of studies: Newcastle–Ottawa Scale",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "3. Presentation of results",
      "text": "Quality of studies: Several of the studies were non-randomized or retrospective, allowing for patient selection bias to influence the results (no further information in the text) • Median OS (95% CI) was eight (5–15) months. Survival rates after one, three, and five years were 29% (20%–40%), 4% (1%–1%), and 1% (0%–5%), respectively. • Only 1% experienced liver failure and 18% had post-treatment complications. • Patients with MPV thrombosis had Worse survival than PVB patients (p < 0.001), but similar mRECIST response rates (14% vs. 16%). Conclusion of authors: TACE is a safe treatment for a highly selected population of HCC patients with PVT gain.",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "a total of 851 patients (20 cohort studies and 20 case reports), of whom",
      "text": "151 (17,7 %) underwent TAE for 196 lesions.\nQualitätsbewertung der Studien: To assess the quality of the selected\nstudies, the Critical Appraisal Skills Programme (CASP) for cohort studies\nwas used. Three items (what are the results of this study, how precise are\nthe results and what are the implications of this study for practice?) of the\nCASP tool were left out of the critical appraisal. Regarding point 6 of the\nCASP tool, a follow-up of at least 12 months was considered appropriate\nto judge the effect on tumour size. The quality of case reports was not\nassessed because of likely selection bias. The Oxford Centre for\nEvidence-Based Medicine Levels of Evidence were determined for all\nstudies, where level 1 is the highest level of evidence, and level 5 the\nlowest.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Qualität der Studien: Among the 20 studies, 18 were considered to provide",
      "text": "level 2b evidence and two level 1b. Seven cohort studies scored ‘yes’ on all\n11 items of the CASP tool. All case reports were considered as level 4\nevidence.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "• Surgical treatment was avoided in 68 of 151 patients (45.0%). Elective",
      "text": "TAE was performed in 49 patients involving 66 HCAs, with 41 of these",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "patients (84%) not requiring surgery.",
      "text": "• Major compounds occurred in eight of 151 patients (5.3%); no death was reported. • Among cohort studies, complete tumour dispersion was observed in 10% of patients, and regression in 75%. 4. Conclusion of the authors: Acute or elective TAE in the management of HCA seems safe. TAE in the elective setting offers a reliable alternative to surgery, considering its minimally invasive and parentyma-sparing properties, and the ability to reduce the size of tumours situated in a difficult anatomical position for surgery.",
      "start_page": 11,
      "end_page": 12
    },
    {
      "heading": "3. Presentation of results",
      "text": "Qualität der Studien: Three RCTs were considered high quality and three\nmoderate quality.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "• No difference in one-year (risk ratio: 0.93, 0.85–1.03, p=0.16), two-year",
      "text": "and three-year survival was observed.\n• Objective response and one-year progression-free survival showed no\nsignificant difference between the two treatments.\n• A statistically significant increase in severe toxicity after",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "chemoembolization was found (risk ratio: 1.44, 1.08–1.92, p=0.01),",
      "text": "oldhough this result could be affected by the heterogeneousity of techniques adopted. 4. Conclusion of the authors: In conclusion, despite these weaknesses, our meta-analysis supports the non-superiority of TACE with respect to TAE, which in turn appeals even occasionally when compared to conventional chemoembolization. These conclusions need to be confirmed in broad non-inferiority trials with a large number of cases, strict selection of patients in terms of tumour births, severality of liver dysfunction (as this strongly affects OS) as well as comorbidities (as these as well affect survival) and standardized modality of endovascular tumality treatment also Wang X-ffcy together with frequency.",
      "start_page": 12,
      "end_page": 13
    },
    {
      "heading": "2016 [23]; Kong",
      "text": "QF et al., 2014 [8]; Ni JY et al.,",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "2013 [15]; Liu Z",
      "text": "et al., 2014 [12]; Cao JH et al.,",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "2014 [3]; Huo YR",
      "text": "and reporting of adverse events.22 In the lack of a better source of evidence, the present meta-analysis appears to provide the most possible solid information on the comparison of TACE with TAE. 1. Question To compare the efficiency and safety of combined radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) with RFA alone for hepatocellular carcinomas (HCC). Population: Patients with HCC Intervention / comparator: combination therapy of TACE and RFA versus i RFA monotherapy Endpoints: Overall survival, recurrence-free survival, major complications Search Period (Actuation of Research): Pubmed, Embase, Cochrane Library, Chinese Biomedical Database (CBM), CBI, and the 23th of Surveys:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "et al., 2015 [7].",
      "text": "Li J et al., 2017 Transcatheter hepatic arterial chemoembolizatio n and sorafenib with hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. See also: Zeng J et al., 2016 • The meta-analysis showed that the combination of TACE and RFA is associated with a significantly longer overall survival (HR = 0.62, 95% CI: 0.49–0.78, p < 0.001) and recurrence-free survival (HR = 0.55, 95% CI: 0.40–0.76, p < 0.001) in contrast with RFA monotherapy. • The spiritually higher incidence of major complications in the combination group did with RFA group did not statically determine the conclusion of RFA monotherapy.",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "3. Presentation of results",
      "text": "Quality of studies: The various studies used different methods of randomization for allocation to the experimental and control groups. Blinding and randomization were determined to be adequate in all of the selected RCTs, whereas only one of these studies adequatly described allocation concealment. The risks of selection, performance, or detection biases were not quantified in any of the included studies. • The TTP increased significantly in the experimental groups (hazard ratio [HR]: 0.82; 95% CI: 0.69–0.97; p = 0.02), but OS did not improve significantly, compared with the control groups. • The risks of hand and foot skin reactions (Hratituder, frequencyr, frequencyr).",
      "start_page": 15,
      "end_page": 16
    },
    {
      "heading": "December 2013.",
      "text": "Anzahl eingeschlossene Studien/Patienten (Gesamt): Five comparative\nstudies (2 were randomized control trials) that included 899 patients\nQualitätsbewertung der Studien: The Delphi list was used to assess the\nquality of the randomized controlled trials. The Newcastle-Ottawa scale\nwas used to assess the quality of the nonrandomized controlled study.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "3. Presentation of results",
      "text": "Quality of the studies: The quality of the data was evaluated for the two included studies that were randomized control trials using the Delphi list. The study of Kudo et al. received 8 points and of Sansonno et al. 7 points, indicating the data were of good quality. A risk for detection bias was present because the outcome assessors in both studies were not blinded. The Sansonno et al. study also did not include an intention-to-treat analysis. The quality of the Bai et al., Muhammad et al. and Qu et al. studies, which were non-randomized, was evaluated using the Newcastle-Ottawa scale. The Bai et al. data were related to high quality as they did a score and select 9.",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "3. Presentation of results",
      "text": "Quality of the studies: All trials included in this analysis were double-blind placebo-controlled randomized phase 3 clinical trials. Efficacy: Compared with controls, sorafenib was shown to significantly increase over survival (OS), time to progression (TTP), and disease control rates (DCR), but not the time to symptom progression (TTSP) in hepatocellular carcinom patients. to ed se rall ma Belinso Local T for Unre Primary Hepatoc Carcino on S e herap esecta y cellul oma et al. pies enable lar Adverse events: The incidence of grade-III/IV adverse reactions, including hand-foot-sk reactions, diarrhea, hypotension and skinrash.",
      "start_page": 17,
      "end_page": 23
    },
    {
      "heading": "Search period (update of the search): until 07/2012",
      "text": "Anzahl eingeschlossene Studien/Patienten (Gesamt): 5 (n=1462)\nQualitätsbewertung der Studien: Two independent reviewers (A.S. and\nC.T.) evaluated the quality of each trial, according to the Cochrane\nHandbook for Systematic Reviews of Interventions.\n3. Ergebnisdarstellung\nQualität der Studien: Two of the studies were found to have a low risk of bias\nand 3 trials had a high risk of bias.\nDCR (n=3 studies):\n• Sorafenib group had an 85% higher response rate than the placebo",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001;",
      "text": "I2=0.0%) TTP (n=5 studies): • sorafenib improvised the TTP significantly over placebo (HR, 0.61; 95% CI, 0.51, 0.73; P<0.001; I2=31.8%) Overall Survival (n=4 studies): • sorafenib treatment improved the survival of patients (HR, 0.71; 95% CI, 0.56, 0.89; P<0.001; I2=46.5%) Adverse events (n=5 studies): • sorafenib increased the incidence of overall AEs, such as fatigue (21.4%), alopecia (24.5%), hand-foot skin reaction (HFSR; 33.2%), or desquamation (23.0%), diarrhea (29.8 %), naa (8%), and activity was found in 4.",
      "start_page": 23,
      "end_page": 24
    },
    {
      "heading": "Guidelines",
      "text": "GUIDELINE QUESTIONS 1]. What are the goals of therapy and recommendations for the treatment of adult patients with: LA • intermediate stage hepatocellular carcinoma? • advanced stage hepatocellular carcinoma? • terminal stage hepatocellular carcinoma? Basis of the guideline This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Team Tumour interpretation of the data. Suchs interpretation of the data.",
      "start_page": 24,
      "end_page": 26
    },
    {
      "heading": "Scheme of Evidence Graduation according to Oxford",
      "text": "In order to classify the risk of distortion of the identified studies, this guideline uses the Oxford Centre for Evidence-based Medicine system in the 2009 version of Table 7. This system provides for the classification of the studies for various clinical issues (benefits of therapy, prognostic significance, diagnostic value). LoE/GoR",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Scheme of Recommendation Graduation",
      "text": "The OL methodology provides for the award of recommendation grades by the guideline authors in a formal consensus procedure. Accordingly, a multi-part nominal group process moderated by the AWMF was carried out. At the end of this group process, the recommendations were formally agreed by the voting mandaters (see Chapter 1.7). The results of the respective votes are assigned to the recommendations according to the categories in Table 9. The guideline includes all evidence-based statements (see Chapter 2.2.3) and recommendations the evidence level (see 2.2.1) of the underlying studies as well as, in the case of recommendations, the strength of the recommendation (level of recommendation). Regarding the strength of the recommendation, three levels of recommendation are distinguished in this guideline (see Table 8), which are also reflected in the formulation of the recommendations. Table 8: Scheme of recommendation degree of recommendation Description Syntax A Strong recommendation should B Recommendation should be open Table 9: Consensus strength Consensus strength Percentage approval Strong consensus > 95% of the voter consent > 75 – 95% of the voter consent",
      "start_page": 28,
      "end_page": 29
    },
    {
      "heading": "As statements, statements or explanations of specific",
      "text": "They are adopted in accordance with the recommendations of a formal consensus procedure and can be based either on study results or expert opinions.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "‘Good Clinical Practice (GCP)' refers to recommendations to:",
      "text": "As a rule, these recommendations address good clinical practice practices for which no scientific studies are required or can be expected. For the graduation of GCPs, no symbols were used, the strength of the recommendation is derived from the formulation used (should/should/can) according to the classification in Table 8. Recommendations on Staging and Classification Consensus-based Recommendation: • The pTNM classification should be used as morphological staging. In order to assess the prognosis of an HCC, the staging system should also consider the tumor stage, liver function and physical performance of the patient as well as the effect of therapy on life expectancy. Therefore, the BCLC classification should be used as an integrated staging in the therapy strategy of the HCC. [GCP; strong consensus] BCLC classification from BCLC General condition Tumor liver function stage A1 ECOG 0 1 stove < 5 cm No portal hypertension A2 A4 B C D Therapie emp ECO ECO ECO ECO",
      "start_page": 29,
      "end_page": 34
    },
    {
      "heading": "See Appendix!",
      "text": "e Documents of other organizations on possible comparators Recommendations 1.1 Sorafenib is recommended as an option for treating advanced attenuating hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment, only if the company provides sorafenib within the agreed commercial access arrangement. 1.2 This recommendation is not intended to affect treatment with sorafenib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangement in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Evidence: 3.1 The approach within the management of the responsibility.",
      "start_page": 34,
      "end_page": 35
    },
    {
      "heading": "Detailed description of the search strategy",
      "text": "Cochrane Library (Cochrane Database of Systematic Reviews, Health Technology Assessment Database) on 02.10.2017",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "# Search question",
      "text": "#1 MeSH descriptor: [Liver Neoplasms] explode all trees #3 hepatoma*:ti,ab,kw or HCC:ti,ab,kw or hepatocarcinoma*:ti,ab,kw or liver cell carcinoma*:ti,ab,kw or hepatocarcinoma*:ti,ab,kw or hepatocellular next carcinoma*:ti,ab,kw or liver cell carcinoma*:ti,ab,kw #4 liver:ti or \"hepatic\":ti or \"hepatocellular\":ti or \"hepatobiliary\":ti #5 cancer*:ti or tumor* or tumour*:ti or neoplasma*:ti or carcinoma* or adenocarcinoma*:ti or malignan*:ti #6 #4 or #3 or #6 #8 #7 Publication Year from 2012 to 2017 (Rechrane Review)",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "# Search question",
      "text": "#1 Carcinoma, Hepatocellular[MeSH Terms] #2 Liver Neoplas[mh:noexact] #3 ((hepatocarcinoma*[Title] OR HCC[Title] #4 (((((cancer*[Title]) OR tumors[Title] OR malignan*[Title] #6 #4 AND #7 #2 OR #3 OR #6 #8 (((addle)) OR adenocaroma*[Title] OR malignan*[Title] #6 #5 #7 #2 OR #3 #6 #6",
      "start_page": 37,
      "end_page": 38
    },
    {
      "heading": "# Search question",
      "text": "#2 Liver Neoplasms[mh:noexp] #3 ((hepatocarcinoma*[Title]) OR hepatoma*[Title] OR HCC[Title] #4 (liver[Title] OR hepatic[Title] OR tumour*[ neoplasm*[Title] OR carcinoma*[Title] OR adenocarcinoma*[Title] #6 #4 AND #5 #1 OR #2 OR #3 OR #6 #7 AND (Guideline[ptype] OR Practice Guideline[ptype] OR guideline* Consensus Development OR #6 #4 AND #5 #2 OR #3 OR #6 #7",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "Literature:",
      "text": "1st Alberta Health Services (AHS). Hepatocellular carcinoma [online]. Edmonton (CAN): AHS; 2015. [Access: 04.10.2017]. (Clinical Practice Guideline; Volume GI 007 Version 6). URL: cancer-guide-gi007-hepatocellular-carcinoma.pdf. 2. Belinson S, Yang Y, Chopra R, Shankaran V, Samson D, Aronson N. Local therapies for unresectable primary hepatocellular carcinoma [online]. Agency for Healthcare Research and Quality (AHRQ); 2013. [Access: 04.10.2017]. URL: unresectable-executive-130524.pdf. 3. Cao JH, Zhou J, Zhang XL, Ding X, Long QY. Meta-analysis on radiofrequency ablation in combination with transarterial chemotherapy for the treatment of hepatocarcioma. J.",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "table under heading <Criteria according to 5. Chapter § 6 VerfO>",
      "text": "Row 1: I. Concomitant therapy: criteria according to Chapter 5. § 6 VerfO G-BA-Row 2: -- Row 3: -- Row 4: Lenvatinib-- Row 5: [for the treatment of liver cell carcinoma]- Row 6: - Row 7: -- Row 8: -- Row 9: criteria according to Chapter 5. § 6 VerfO- Row 10: - Row 11: If a medicinal product application is considered as a comparative therapy, the medicinal product must in principle have an authorisation for the application area.--See overview \"II. Approved medicinal products in the application area--- Row 12: If a non-medical treatment is considered as a comparative therapy, it must be enforceable within the scope of the GKV.--Non-medical treatment is not considered as an appropriate comparative therapy.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table under heading <Tradename>",
      "text": "The following are currently being used in the treatment of the liver cell carcinoma Row 16: Lenvima® to target the following metastasizing tumours:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Trade name> (column 1)",
      "text": "Row 1: ATC-Code----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Trade name> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: ormation) Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Trade name> (column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: ) Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Trade name> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Indication:> (from previous page)",
      "text": "Row 1: Akdae 20-Arzneimittelkommission der deutschen Ärzteschaft Row 2: AWMF-Arzneimittelkommission Row 2: AWMF-Arzneimitschaft der wissenschaftliche medizinische Fachgesellschaften Row 3: ÄZQ-Arztliches Zentrum für Qualität in der Medizin Row 4: CASP-Critical Appraisal Skills Programme Row 5: CCO-Cancer Care Ontario Row 6: DHTA-Deutsche Agentur für Health Technology Assessment Row 7: DCR-Disease control rate Row 8: DRKS-Deutsches Register Klinischer Studien Row 9: ESMO-European Society for Medical Oncology Row 10: G-BA-Joint Federal Committee Row 11: GIN-Guidelines International Network Row 12: HCC-Hepatozellular Carcinoma Row 13: HFSR-Hand and foot skin reactions Row 14: ICTRP-Internal Trials Registry Platform Row 15: IQWiG-Institut für Qualität und Wirtschaftlichkeitung im Gesundheit Row 16: IFSR-Nov-International Control",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "table under heading <Indication:> (from previous page)",
      "text": "Row 1: G-BA, 2015 [5]. Decision of the Joint Federal Committee on an amendment of the decision on measures for quality assurance in proton therapy in patients with inoperable hepatocellular carcinoma (HCC): Extension of validity period See also: G-BA, 2015 [6].",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table under heading <Cochrane Reviews>",
      "text": "Row 1: noccarina D et al., 2017 [17]. Management of people with intermediate- stage hepatocellular carcinoma1. Question To assess the comparative benefits and harms of different interventions used in the treatment of intermediate-stage hepatocellular carcinoma (BCLC stage B) through a network meta-analysis and to generate rankings of the available interventions according to their safety and efficiency. Row 2: .2. Methodology Population: Participations with intermediate-stage hepatocellular carcinoma (BCLC stage B) irrelevant of the presence of Cirrhosis, size and number of the tumours (they met the criteria of intermediate-stage hepatocellular carcinoma)",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table under heading <Systematic Reviews>",
      "text": "Row 1: chemoembolisation (where anti-cancer drugs block the blood supply and treat the cancer through the vessels supplying the cancer), chemotherapy using sorafenib (a drug which blocks cancer growth), or a combination of transarterial chemoembolisation and sorafenib. Quality assessment of studies: Cochrane risk of bias / GRADE Row 2:",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heading <Systematic Reviews>",
      "text": "Row 1: Silva JP et al., 2017 [19]. Transarterial chemoembolizatio n in hepatocellular|1. Fragestellung This systematic review sought to examine the role of TACE in the treatment of HCC with PVT in either the main portal vein (MPV) or portal vein branches (PVB).\nRow 2: |2. Methodik",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heading <3. Display of results>",
      "text": "Row 1: carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysm •Population: HCC patients with PVT. Intervention / comparator: comparing TACE to another treatment for management of HCC with PVT Endpoints: overall survival (OS), mRECIST response, and compliance incidence Search period: PubMed was searched from January 1, 2006 to August 31, 2016. Number of included studies/patients (total): 13 studies with 1933 TACE patients were included. Quality assessment of studies: Newcastle–Ottawa Scale Row 2:",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table under heading <patients (84%) not requiring surgery.>",
      "text": "Row 1: adenomas:Note: Studies considering hepatic malignancies and tumours other than HCA, those reporting techniques other than TAE (such as radiofrequency ablation or hepatic artery ligation) and reviews were excluded. Endpoints: tumour size, malignant transformation or adverse events. Search period: systematic literature search, up to 7 January 2016, of the PubMed and Embase databases was undertaken Number of included studies/patients (total): 40 articles included a total of 851 patients (20 cohort studies and 20 case reports), of who 151 (17.7%) underwent TAE for 196 lessons.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table under heading <chemoembolization was found (risk ratio: 1.44, 1.08–1.92, p=0.01),>",
      "text": "Rows of disease disease A et al., 2017 [4]. Transarterial chemoembolizatio n vs bland embolization in hepatocellular cancera: A meta-analysis of randomized trials1. Question The objective of this article is to systematically analyze the results provided by randomized controlled trials compared these two treatments in hepatocarcinoma patients. Row 2: 的2. Methodology Population: hepatocarcinoma patients Intervention / Comparator: TACE vs. TAE Endpoints: Survival rates assessed at one, two, and three years, respectively response, one-year progression-free survival, and several adverse event rate Search period (Aktualität der Recherche): PubMed/Medline, Embase liybra 2016",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading <2014 [3]; Huo YR>",
      "text": "Row 1: and reporting of adverse events.22 In the lacquer of a better source of evidence, the present meta-analysis appears to provide the most possible solid information on the comparison of TACE with TAE. Row 2: Wang X et al., 2016 [22]. Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolizati on for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis See also: Wang Y et al., 2016 [23]; Kong QF et al., 2014 [8]; Ni JY et al., 2013 [15]; Liu Z et al., 2014 [12]; Cao JH et al., 2014 [3]; Huo YR",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under heading <et al., 2015 [7].>",
      "text": "Row 1: et al., 2015 [7].-• The meta-analysis showed that the combination of TACE and RFA is associated with a significantly longer overall survival (HR = 0.62, 95% CI: 0.49–0.78, p < 0.001) and recovery-free survival (HR = 0.55, 95% CI: 0.40–0.76, p < 0.001) in contrast with RFA monotherapy. • The slightly higher incidence of major complications in the combination group compared with RFA group did not reach statistical significance. Row 2:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heading <et al., 2015 [7].> (column 2)",
      "text": "Row 1: • The meta-analysis showed that the combination of TACE and RFA is associated with a significantly longer overall survival (HR = 0.62, 95% CI: 0.49–0.78, p < 0.001) and recovery-free survival (HR = 0.55, 95% CI: 0.40–0.76, p < 0.001) in contrast with RFA monotherapy. • The considerably higher incidence of major complications in the combination group compared with RFA group did not reach statistical significance. Row 2: 4. Conclusion of the authors: In conclusion, this meta-analysis suggested that the combination of TACE and RFA is associated with significantly higher overall survival and recovery.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heading <3. Display of results>",
      "text": "Row 1: [26].-RCTs were included in the meta-analysis with a total of 877 HCC cases from 14 countries, including China and the USA. Quality assessment of the studies: Quality assessment was performed based on the following criteria: Allocation was sufficently randomized; blinding for allocation was sufficient; and loss to follow-up or exit status were evaluated. Row 2: 3. Results presentation Quality of the studies: The various studies used different methods of randomization for allocation to the experimental and control groups. Blinding and randomization were determined to be accurate in all the selected RCTs, where only one of the these studies adequatly disinfected incidence.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "table under heading <3. Display of results>",
      "text": "Row 1: Wang G et al., 2016 [21]. Sorafenib combined with transarterial chemoembolizatio n in patients with hepatocellular carcinoma. See also: Zhang L et al., 2014 [27].",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heading <3. Result representation> (column 2)",
      "text": "Row 1: 1. Question This study evaluated the efficiency and safety of TACE + sorafenib. Row 2: 2. Methodology Population: patients with advanced HCC Intervention/Comparator: TACE vs. TACE + Sorafenib Endpoints: The primary outcome measure was time to progression (TTP), and the secondary outcomes measures were overall survival (OS) and adverse events. Search period: MEDLINE, the Cochrane Library, EMBASE, and the ISI Web of Knowledge were searched until 31 December 2013. Number of included studies/patients (total): Five comparative studies (2 were randomized control trials)",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heading <3. Display of results>",
      "text": "Row 1: 的improved OS. Additional randomized controlled studies are necessary to further investigate the clinical benefit of TACE + sorafenib in treating advanced HCC Row 2: Wang Z et al., 2013 [24]. Meta-analysis of the Efficacy of Sorafenib for Hepatocellular Carcinoma1. Question by carrying out out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy-based, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which means proven clinical practice guidelines of evidence-based. Row 3:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "table under heading <3. Result representation> (from previous page)",
      "text": "Row 1: additional events: The incidence of grade-III/IV adverse reactions, including hand-foot-skin reactions, diarrhea, hypertension and skin crash or desquamation, in sorafenib treatment group was higher than that in controls. However, there was no significant difference in the incidence of hypodynamia between the two groups. Row 2: .4. Conclusion of the authors: Sorafenib exerts significant curative effects in hepatocellular carcinoma. Row 3: Belinson S et al., 2013 [2]. Local therapies for Unresectable Primary Hepatocellular Carcinoma  while1.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "table under heading <3. Result representation> (from previous page)",
      "text": "Row 1: as • Child-Pugh class A or B disease • Eastern Cooperative Oncology Group (ECOG) status ≤1 and/or • BCLC stage A or B, or equivalent Intervention / Comparator: Local therapies (see Part of Results) Endpoints: overall survival and quality of life—and various adverse events Search period: MEDLINE and Embase from January 2000 to July 2012 Number of included studies/patients (total): See Part of Results! Quality Assessment of Studies: In the Assessment of risk of bias in individual studies, we followed the Agency for Healthcare Research and Quality (AHRQ)",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "table under heading <3. Result representation> (from previous page)",
      "text": "Row 1: 的4. Conclusion of the authors: (...) For the comparison of RFA to PEI/PAI, our conclusions suggest that for these patients treatment with RFA conferences a survival benefit at 3 years compared with PEI/PAI. In addition, TTP and local recovery may be improved in patients treated with RFA compared with PEI/PAI. Patients treated with RFA also feel to have longer LOS after treatment compared with those treated with PEI/PAI. Beyond this evidence on the comparative effectiveness of these procedures was insufficient. Subsequent analyses had on later treatment compared with those treated with PEI/PAI. Beyond this evidence on the comparative efficiency of these offences was insufficient. Subsequent analyses had on later treatment compared with those treated with PEI/PAI.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "table under heading <3. Result representation> (from previous page, column 2)",
      "text": "Row 1: 4. Conclusion of the authors: (...) For the comparison of RFA to PEI/PAI, our associations suggest that for these patients treatment with RFA conferences a survival benefit at 3 years compared with PEI/PAI. In addition, TTP and local recovery may be improved in patients treated with RFA compared with PEI/PAI. Patients treated with RFA also feel to have longer LOS after treatment compared with those treated with PEI/PAI. Beyond this evidence on the comparative effectiveness of these procedures was insufficient. Subsequent comparisions had only one or no comparative studies on a given treatment comparison. For these evaluations, evidence was required for all outcomes; compliance in respect of the compliance.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "table under heading <3. Result representation> (from previous page)",
      "text": "• TTP benefit existing in the sorafenib group when compared with the control group (HR=0.69, 95% CI: 0.55, 0.86; P=0.001) • heterogeneity was significant (P=0.000, I2=84.4%) • subgroup analysis: significant TTP benefits of sorafenib treatment in the patients irrelevant of MVI, EHS, and ECOG status • Begg and Egger tests provided no evidence of publication bias Overall response rate (n=5 studies): • sorafenib did not have a higher ORR when compared with other treatments (RR=0.85, 95% CI: 0.65, P=010) • Begg and Egger test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table under heading <3. Display of results> (from previous page, column 4)",
      "text": "Row 1: Time to progression (n=6 studies): • TTP benefit existing in the sorafenib group when compared with the control group (HR=0.69, 95% CI: 0.55, 0.86; P=0.001) • heterogeneity was significant (P=0.000, I2=84.4%) • Subgroup analysis: significant TTP benefits of sorafenib treatment in the patients irrelevant of MVI, EHS, and ECOG status • Begg and Egger tests provided no evidence of publication bias Overall response rate (n=5 studies): • sorafenib did not have a higher ORR when compared with other treatments (RR=0.85, 95% CI: 0.65, 1.11; P=0.10) • Begg and Egger tests performed without error (RR).",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table under heading <3. Result representation> (from previous page)",
      "text": "Row 1: All-cause mortality (n=5 studies): • no significant effect of all-cause mortality (RR=1.21, 95 % CI=0.74–1.98, P=0.16) Survival (n=5 studies): • 1-year survival did not differ between TACE and TAE (RR=0.92, 95 % CI=0.83–1.01, P=0.53) Tumor response rates(n=1 study) • No significant difference were observed between TACE and TAE Adverse events (n=k. A.) • The most common adverse events were post-TACE syndrome (pain, five, nausea, vomiting). • In the TACE group, the incidence of nausea and from the following approaches were Tcread Ttrade and Ttrade group • AE.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "table under heading <3. Result representation> (from previous page, column 2)",
      "text": "Row this 1: All-cause mortality (n=5 studies): • no significant effect of all-cause mortality (RR=1.21, 95 % CI=0.74–1.98, P=0.16) Survival (n=5 studies): • 1-year survival did not differ between TACE and TAE (RR=0.92, 95 % CI=0.83–1.01, P=0.53) Tumor response rates(n=1 study) • No significant difference were observed between TACE and TAE Adverse events (n=k. A.) • The most common adverse events were post-TACE syndromes (pain, five, nausea, vomiting). • In the TACE group, the incidence of nausea and vomiting appeal attended events were compared with TACE.AE.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "table under heading <group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001;>",
      "text": "Row 1: With Unresectable Hepatocellular Carcinoma.-Population: Child-Pugh A patients with unresectable HCC Intervention: sorafenib Comparator: placebo Endpoints: disease control rate (DCR), time to progression (TTP), overall survival (OS), adverse events Definition DCR: DCR was defined as the percentage of patients who had a complete response, a partial response or stable disease (according to RECIST) that was maintained for at least 28 days after the first demonstration of that rating. Search period (admission of research): until 07/2012 Number of studies/patients included (total): 5 (n=1462) Quality assessment of studies: Two independent reviews (A.S. and C.T.)",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "table under heading <group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001;> (column 4)",
      "text": "Row 1: Population: Child-Pugh A patient with unresectable HCC Intervention: sorafenib Comparator: placebo Endpoints: disease control rate (DCR), time to progression (TTP), overall survival (OS), adverse events Definition DCR: DCR was defined as the percentage of patients who had a complete response, a partial response or stable disease (according to RECIST) that was maintained for at least 28 days after the first demonstration of that rating. Search period (actuality of the research): up to 07/2012 Number of included studies/patients (total): 5 (n=1462) Quality assessment of studies: Two independent reviews (A.S. and C.T.) Evaluation of quality of each trial, tricording to the frequency of the frequency of the frequency of response.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "table under heading <Guidelines>",
      "text": "Row 1: Alberta Health Services, 2015 [1]. HEPATOCELLULA R CARCINOMA的GUIDELINE QUESTIONS What are the goals of therapy and recommendations for the treatment of adult patients with: • intermediate stage hepatocellular carcinoma? • advanced stage hepatocellular carcinoma? • terminal stage hepatocellular carcinoma? Row 2: 的Methodic Basis of Guideline This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "table under heading <Guidelines>",
      "text": "Row 1: Level-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "table under heading <Guidelines> (column 4)",
      "text": "Row 1: GUIDELINE AND QUESTIONS What are the goals of therapy and recommendations for the treatment of adult patients with: • intermediate stage hepatocellular carcinoma? • advanced stage hepatocellular carcinoma? • terminal stage hepatocellular carcinoma? Row 2: Methodology Basis of the Guideline This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Tumour Team.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "table under heading <Guidelines> (from previous page)",
      "text": "Row 1: 的 Row 2: DKG, 2013 [9.10]. Diagnosis and/or challenge: Recommendations for the diagnosis and therapy of hepatocellular carcinoma Row 3: 的Methodik",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "table under heading < Schema of evidence grading according to Oxford>",
      "text": "Row 1: Therapy of hepatocellular carcinoma The basis of the guideline Basis of the guideline: The development of the guideline was carried out in a structured process according to the AWMF rulebook (http://www.awmf.org/Guidelines/awmf-regelwerk.html). In advance, the guideline was structured according to various thematic complexes. The key questions were identified in the interdisciplinary consensus at the first working meeting (Kick-off-Meeting). In order to answer the key questions, a concept was developed for their comparative presentation with the statements of international guidelines and the literature underlying them. In a second meeting with all mandaters of the different specialist societies and institutions, it was clarified on which basis (de-Novo-recherche, guideline adaptation or pure expert consensus) the key questions should be answered. Search period: In October 2009 and January 2010 the central and systematic search for guidelines for the diagnosis and therapy of hepatocellular carcinoma was published by Low.",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table under heading <Schema of evidence grading according to Oxford> (from previous page)",
      "text": "Row 1: |",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table under heading < Schema of recommendation grade>",
      "text": "Row 1: Scheme of Recommendation Graduation The OL methodology provides for the award of degree of recommendation by the guideline authors in a formal consensus procedure. Accordingly, a multi-part nominal group process moderated by the AWMF was carried out. At the end of this group process, the recommendations were formally coordinated by the voting representatives (see Chapter 1.7). The results of the respective votes are assigned to the recommendations according to the categories in Table 9. The guideline describes all evidence-based statements (see Chapter 2.2.3) and recommendations the evidence level (see 2.2.1) of the underlying studies and, in the case of recommendations, the strength of the recommendation (level of recommendation). In terms of the strength of the recommendation, three levels of recommendation are distinguished in this guideline (see Table 8), which are also reflected in the formulation of the recommendations.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP)] is called recommendations, too>",
      "text": "Row 1: Table 8: Scheme of recommendation graduation Degree of recommendation Description Syntax A Strong recommendation should B Recommendation should C Recommendation open Table 9: Consensus strength Consensus strength Percentage approval Strong consensus > 95% of the voting rights Consensus > 75 – 95% of the voting rights Majority approval > 50 – 75% of the voting rights Dissent < 50% of the voting rights Statements Statements are described as statements or explanations of specific issues or questions without direct request for action. They are adopted according to the procedure of the recommendations in a formal consensus procedure and can be based either on study results or expert opinions. Good Clinical Practice (GCP) \"Good Clinical Practice (GCP)\" means recommendations to which no literature research has been carried out. As a rule, these recommendations address approaches of good clinical practice, for which no scientific studies are required or can be expected.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP)] is called recommendations, too>",
      "text": "Row 1: Recommendation grade::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP)] is called recommendations, too>",
      "text": "Row 1: Consensus-Strength of Consensus-Percentage of Consensus Row 2: Strong Consensus-Percentage of Consensus-Percentage of Consensus-Percentage of Consensus-Percentage of Consensus-Persons-Persons-Persons-Persons-Persons-Persons Row 3: Consensus-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Persons-Per",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP)] is called recommendations, too>",
      "text": "Row 1: BCLC Stadium-General condition-Tumor-Liver function Row 2: A1-ECOG 0-E Stove < 5 cm-No portal hypertension",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP) to> (from previous page)",
      "text": "Row 1: normal bilirubin A2 ECOG 0 1 stove < 5 cm portal hypertension normal bilirubin A3 ECOG 0 1 stove < 5 cm portal hypertension bilirubin increased A4 ECOG 0 1 stove < 5 cm Child-Pugh A or B ECOG 0 large multilocular Child-Pugh A or B C ECOG 1-2 vascular invasion Child-Pugh A or metastases or B D ECOG 3-4 no matter Child-Pugh C therapy recommendations:",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP) to> (from previous page)",
      "text": "Row 1: normal bilirubin Row 2: A2-ECOG 0-01 Herd < 5 cm--portal hypertension normal bilirubin Row 3: A3-ECOG 0-01 Herd < 5 cm--portal hypertension bilirubin increased Row 4: A4-ECOG 0-01 Herd < 5 cm---Child-Pugh A or B Row 5: B-ECOG 0--large multilocular--Child-Pugh A or B Row 6: C-ECOG 1-2----vessel invasion or metastases---Child-Pugh A or B Row 7: DECOG 3-4-----egal---Pugh C",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP) to> (from previous page)",
      "text": "Row 1: Transarterial procedures Patient selection for the implementation of a transarterial procedure Evidence-based recommendation: • Transarterial chemoembolisation (TACE) should be performed in patients in whom a curative procedure is not possible and which have the following criteria: solo or multifocal HCC without extrahepatic metastasis and ECOG ≤ 2, in stage CHILD-Pugh A or B. [LoE: 1b; GoR: A; strong consensus] Consensus-based recommendation: • The indication for transarterial chemoembolisation (TACE) should be provided in an interdisciplinary tumor board. [GCP; strong consensus] • In individual cases, transarterial chemoembolisation (TACE) may be considered in non-leading systemic metastasis. [GCP; strong consensus] • Transarterial chemoembolisation (TACE) in patients with segmental pfort vein thrombosis. [GCP; strong consensus HCP] In the event of systemic therapy, the liver is restricted to a stage.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP) to> (from previous page)",
      "text": "Row 1: can be performed with ECOG status 0-2 and a life expectancy of > 3 months, a system therapy with sorafenib should be offered. [LoE: 1a; GoR: A; strong consensus] Guidelines adaptation [1] • Except sorafenib, a system therapy with individual substances, a combination chemotherapy, intraarterial chemotherapy or a combination of chemotherapy and radiotherapy should only be carried out in clinical trials. [LoE: 2a; GoR: B; strong consensus] Guidelines adaptation [1] Consensus-based recommendation: • Palliative therapy with sorafenib should not be continued beyond symptomatic and radiological progress. The toxicity of the therapy should be closely monitored and taken into account. [GCP; strong consensus] Evidence-based statement: • In HCC patients in the stage Child-Pugh B, no survival benefit for sorafenib therapy has been demonstrated. [LoE: 3b; strong consensus] Evidence-based recommendation: • In HCC patients in the stage Child-Pugh B, there is no recommendation for sorafenib therapy.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP) to> (from previous page, column 3)",
      "text": "Row 1: can be performed with an ECOG status 0-2 and a life expectancy of > 3 months, a system therapy with sorafenib should be offered. [LoE: 1a; GoR: A; strong consensus] Guidelines adaptation [1] • Except sorafenib, a system therapy with individual substances, a combination chemotherapy, intraarterial chemotherapy or a combination of chemotherapy and radiotherapy should only be carried out in clinical trials. [LoE: 2a; GoR: B; strong consensus] Guidelines adaptation [1] Consensus-based recommendation: • Palliative therapy with sorafenib should not be continued beyond symptomatic and radiological progress. The toxicity of the therapy should be closely monitored and taken into account. [GCP; strong consensus] Evidence-based statement: • In HCC patients at stage child-pugh B no survival benefit for sorafenib therapy is to be demonstrated. [LoE: 3b; stronger consensus] Evidence-based recommendation: • In HCC patients at stage child-pugh; consensus should not be performed in stage.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "table under heading <Good Clinical Practice (GCP) to> (from previous page)",
      "text": "Row 1: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table under heading > See Appendix!>",
      "text": "Row 1: See Appendix!",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table under heading > See Appendix!>",
      "text": "This acceptance is not intended to affect treatment with sorafenib thatwas started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table under heading <# Search question>",
      "text": "Row 1: and search Row 2: #1-MeSH descriptor: [Carcinoma, Hepatocellular] explode all trees Row 3: #2-MeSH descriptor: [Liver Neoplasms] explode all trees Row 4: #3-hepatoma*:ti,ab,kw or HCC:ti,ab,kw or hepatocarcinoma*:ti,ab,kw or hepatocellular next carcinoma*:ti,ab,kw or liver cell carcinoma*:ti,ab,kw Row 5: #4-liver:ti or \"hepatic\":ti or \"hepatocellular\":ti or \"hepatobiliary\":ti Row 6: #5-cancer* or tumor* or tumour*:ti or neoplasma*:ti or carcinoma* or adenocarcinoma*:ti or malignan*:ti Row 7: #6-ray",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "table under heading <# Search question>",
      "text": "Row 1: [[Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [Item] [it] [Item] [Item] [it] [Item] [Item] [it] [it] [Item] [it] [it] [it] [Item] [it] [it] [it] [it] [it] [it] [it] [it] [it] [it] [it]",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "table under heading <# Search question>",
      "text": "Row 1: (systematic*[Title/Abstract] AND overview*[Title/Abstract]) OR meta- analy*[Title/Abstract] OR (meta[Title/Abstract] AND analyzez*[Title/Abstract]) OR (meta[Title/Abstract] AND analyzet*[Title/Abstract]) OR (((review*[Title/Abstract]) OR overview*[Title/Abstract]) AND ((evidence[Title/Abstract] AND analyzet*[Title/Abstract])) OR ((((review*[Title/Abstract]) OR overview*[Title/Abstract] AND ((evidence[Title/Abstract]) AND based[Title/Abstract]) AND [Title/Abstract])",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "table under heading <# Search question>",
      "text": "Row 1: [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2] [2 [2] [2] [2] [2] [2 [2] [2 [2] [2] [2 [2] [2] [2] [2] [2] [2] [2 [2] [2] [2] [2] [2] [2] [2] [2 [2] [2] [2 [2] [2] [2 [2 [2 [2] [2",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "table under heading <# Search question> (column 1)",
      "text": "Row 1: Row 2: #14 Row 3: #15",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "table under heading <# Search question> (column 1)",
      "text": "Row 1: #the search question Row 2: #1the Row 3: #2the Row 4: #3the Row 5: #4the Row 6: #5the Row 7: #6the Row 8: #7the Row 9: #8the Row 10: #9the",
      "start_page": 38,
      "end_page": 38
    }
  ]
}